Notice: Fall 2017 exams affected by natural disasters... More >

Expand/Collapse Close

ABIM knows that we have many physicians whose lives have been upended by recent natural disasters. If you live or work near an affected area, we understand that the weather may have impacted your ability to take your Fall 2017 exam as scheduled. We have developed a series of options to help you get through this process as smoothly as possible. If you have any questions, please call us at 1-800-441-ABIM (2246) or email request@abim.org.

American Board of Internal Medicine home page

MOC is a professionally determined standard that attests that an internist is staying current in knowledge and practice throughout his/her career.

Initial Certification indicates that physicians have met rigorous standards through intensive study, accredited training and evaluation and that they have the clinical judgment, skills and attitudes essential for the delivery of excellent patient care.

For more than 75 years, Certification by ABIM has stood for the highest standard in internal medicine and its 20 subspecialties.

Endocrinology, Diabetes, and Metabolism Board Exam Committee

Paul W. Ladenson, MD, Chair

Dr. Ladenson, a board certified internist and endocrinologist, is the John Eager Howard Professor of Endocrinology and Metabolism and Director of the Division of Endocrinology, Diabetes, & Metabolism at the Johns Hopkins Medical Institutions, where he is Professor of Medicine, Pathology, Oncology, and Radiology and Radiological Sciences, as well as a University Distinguished Professor. He is also Professor of International Health at the Johns Hopkins Bloomberg School of Public Health. His academic career has been as a clinical investigator and educator in thyroidology, and his principal research interests have been thyroid hormone actions on the heart, thyroid cancer, thyroid hormone analogs and health economic analyses related to clinical endocrinology.

Dr. Ladenson serves as a member of the American Board of Internal Medicine (ABIM) Endocrinology, Diabetes, and Metabolism Board as well as Chair of the the ABIM Endocrinology, Diabetes, and Metabolism Board Exam Committee. He is past Editor-in-Chief of the Journal of Clinical Endocrinology & Metabolism, and has served in the past as President of the Association of Program Directors in Endocrinology and Metabolism, the Association of Subspecialty Professors and the American Thyroid Association.

Dr. Ladenson graduated summa cum laude from Dartmouth College with a degree in English literature, from Oxford University with a degree in physiology, and from Harvard Medical School (AOA). He trained as a resident in internal medicine and as a clinical and research fellow in endocrinology at Massachusetts General Hospital.

As of January 2017, Dr. Ladenson reported the external relationships:

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:

  • Veracyte, providing advice regarding clinical and health-economic research related to molecular genetic testing for differential diagnosis of thyroid nodules, receiving compensation for travel expenses and honoraria.
  • Viking Therapeutics, providing advice regarding preclinical and clinical research related to applications of thyromimetic compounds to metabolic disorders, receiving honoraria.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, receiving honoraria:

  • Sentier Therapeutics, for providing advice regarding preclinical and clinical research related to compounds for thyroid hormone therapy.
  • Veracyte, receiving support for lectures to regional professional societies.

Shehzad S. Basaria, MD

Dr. Basaria is a Reproductive Endocrinologist and the Medical Director of the Section of Men's Health, Aging and Metabolism at the Brigham and Women's Hospital, Harvard Medical School. He is board certified in Endocrinology, Diabetes, and Metabolism.

Dr. Basaria is a clinical investigator in the field of male reproductive endocrinology. His research interests include the role of testosterone in pain perception, age-related androgen deficiency and cardiometabolic consequences of androgen deprivation therapy in men with prostate cancer. Dr. Basaria also provides clinical care to patients with male reproductive disorders. Additionally, he is a mentor to junior faculty and endocrine fellows pursuing their careers in reproductive endocrinology.

Dr. Basaria is a member of the American Board of Internal Medicine Endocrinology, Diabetes, and Metabolism Board Exam Committee. He is the Associate Editor of the Journal of Gerontology Medical Sciences, and also serves on the editorial boards of the Journal of Clinical Endocrinology and Metabolism and Endocrine Practice. Previously, Dr. Basaria led the section on Male Reproduction on the Self-Assessment Committee of the Endocrine Society. He was also previously involved in developing the Endocrine Society's Male Androgen Deficiency Performance Improvement Module, which practicing endocrinologists utilize towards their Maintenance of Certification. Dr. Basaria serves as a member of the National Institute of Child Health and Development's Special Emphasis Panel on Male Contraception.

Dr. Basaria received his medical degree from the Aga Khan University in Karachi, Pakistan. He completed house staff training at the University of Texas Health Science Center at Houston and his endocrine fellowship at the Johns Hopkins University School of Medicine.

As of January 2017, Dr. Basaria reported no external relationships.

Daniel H. Bessesen, MD

Dr. Bessesen is Professor of Medicine at the University of Colorado, School of Medicine (UCSOM) and Chief of Endocrinology at Denver Health Medical Center. He is also the Fellowship Program Director for Fellowship Training in Endocrinology, Metabolism and Diabetes at the UCSOM and Associate Director of the Anschutz Health & Wellness Center. He is board certified in Internal Medicine and Endocrinology, Diabetes and Metabolism.

Dr. Bessesen has conducted National Institutes of Health (NIH) and Patient-Centered Outcomes Research Institute funded research in dietary fat metabolism, body weight regulation and the clinical problem of obesity at the University of Colorado and Denver Health Medical Center for more than 25 years. He is a member of the American Board of Internal Medicine Endocrinology, Diabetes and Metabolism Board Exam Committee. He previously served on and chaired the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) C study section which evaluates grant applications for trainees and training programs in nutrition and gastroenterology. Dr. Bessesen also served on and chaired the NIH NIDDK Clinical and Integrative Diabetes and Obesity (CIDO) study section which reviews patient oriented research grant applications related to the prevention, pathogenesis and treatment of diabetes and/or obesity. He was a member of the Clinical Practice Guideline writing group for the Endocrine Society's guideline on the Pharmacological Management of Obesity and he served as the Chair of the Obesity Expert Panel for the Endocrine Society. He is a past recipient of the Roland L. Weinsier Award for Excellence in Medical/Dental Nutrition Education and the Physician Nutrition Specialist Award from the American Society for Nutrition.

Dr. Bessesen received a degree in chemistry from Colorado State University and his medical degree from UCSOM. He completed a residency and chief residency in internal medicine at the University of Colorado and a fellowship in endocrinology also at the University of Colorado.

As of January 2017, Dr. Bessesen reported the following external relationships:

Service on data and safety monitoring boards for the following company, with honoraria:

  • EnteroMedics, Inc., for a study on the safety and efficacy of a vagal blocking device for the treatment of obesity.

Mary T. Korytkowski, MD

Dr. Korytkowski is board certified in Internal Medicine and Endocrinology, Diabetes and Metabolism. She is a Professor of Medicine and interim Chief of the Division of Endocrinology at the University of Pittsburgh. She chairs the University of Pittsburgh Medical Center (UPMC) Diabetes Patient Safety Committee. She has administrative, research and clinical responsibilities.

Dr. Korytkowski previously served as Medical Director of the Pittsburgh Diabetes Center (1989 to 1992) and Medical Director of the UPMC Center for Diabetes and Endocrinology from 1995 through 2006.

She is a member of the American Board of Internal Medicine Endocrinology, Diabetes, and Metabolism Board Exam Committee, and has served as a member of the Professional Practice Committee, the National Board of Directors and the Research Grant Review Committee for the American Diabetes Association (ADA). Dr. Korytkowski was the ADA Chair of the writing group for the American Association of Clinical Endocrinologists/ADA consensus statement on inpatient glycemic control, and a writing group member for the Endocrine Society Clinical Practice Guideline on Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting. She was a writing group member for the ADA Consensus Report on Diabetes in Older Adults. She also served as a member of the Clinical Guidelines Committee for the Endocrine Society and currently serves on the Editorial Board for the Journal of Clinical Endocrinology and Metabolism. She is an Associate Editor of the British Medical Journal Open Diabetes Research & Care.

Dr. Korytkowski received her bachelo's degree in nursing from D'Youville College in Buffalo, New York; a master's degree in nursing from Emory University in Atlanta, Georgia; and her medical degree from the University of North Carolina, Chapel Hill. She completed residency training in internal medicine at Baltimore City Hospital and fellowship training in endocrinology and metabolism at Johns Hopkins Hospital and Sinai Hospital in Baltimore.

As of January 2017, Dr. Korytkowski reported the following external relationships:

Dr. Korytkowski co-directs the Endocrine Disorders Course for second-year medical students at the University of Pittsburgh and oversees development of course examination.

She also serves as the Data and Safety Monitoring Board Chair of a study funded by the Department of Defense.

Eric Orwoll, MD

Dr. Orwoll, board certified in Internal Medicine and Endocrinology, Diabetes, and Metabolism, is Professor of Medicine and Attending Physician in the Bone and Mineral Section of the Division of Endocrinology, Diabetes, and Clinical Nutrition at Oregon Health & Science University.

He has held a variety of leadership positions. He has been the Chief, Section of Endocrinology and Metabolism at the Portland VA Medical Center, and at OHSU he has been the Director of the Bone and Mineral Clinic and Bone Densitometry Services, Director of the Bone and Mineral Research Unit, and Head of the Bone and Mineral Section, Division of Endocrinology, Diabetes, Clinical Nutrition. He is an experienced institutional leader in academic medicine, and has had extensive responsibilities for clinical and translational research at OHSU. He has been the Chair of the Research Committee of the School of Medicine, Director of the General Clinical Research Center, the Associate Vice-President for Research, Associate Dean for Clinical Research in the School of Medicine, and the Director of the Oregon Clinical and Translational Research Institute.

Outside OHSU, he has been a member of numerous editorial boards, the Board of Directors of the National Osteoporosis Foundation, the Council of the American Society for Bone and Mineral Research, and the Scientific Advisory Board of the International Osteoporosis Foundation. Dr. Orwoll is a member of the American Board of Internal Medicine Endocrinology, Diabetes, and Metabolism Board Exam Committee. He is an internationally recognized expert in the area of age-related musculoskeletal change, particularly bone biology and metabolic bone disease. He has been the principal investigator for many projects supported by the the National Institutes of Health, Veterans Administration and foundations. Dr. Orwoll is the author of more than 350 peer-reviewed publications, as well as numerous reviews, books and book chapters.

Dr. Orwoll received a zoology degree from the University of Michigan and his medical degree from the University of Maryland. He completed his house staff training at Providence Medical Center and OHSU in Portland.

As of January 2017, Dr. Orwoll reported the following external relationships:

Funding for research project and staff, paid to Oregon Health & Science University, from the following company:

  • Eli Lilly & Company, for an investigator-initiated research project.

Work as an author or editor for following companies, with compensation as listed:

  • Elsevier, receiving compensation as an editor.
  • Springer, receiving compensation as an editor.

Dr. Orwoll occasionally serves as an expert on legal issues (e.g., suits that involve medical liability.)

Elizabeth R. Seaquist, MD

Dr. Seaquist is a Professor of Medicine at the University of Minnesota where she holds the Pennock Family Chair in Diabetes Research. She also is the Director of the Division of Endocrinology and Diabetes in the Department of Medicine. She is board certified in Internal Medicine and Endocrinology, Diabetes, and Metabolism.

Dr. Seaquist was the 2014 President, Medicine & Science, of the American Diabetes Association. She is also a member of the American Board of Internal Medicine Endocrinology, Diabetes, and Metabolism Board Exam Committee.

Dr. Seaquist is a clinical investigator interested in the complications of diabetes. Her research focuses on the effect of diabetes on brain metabolism, structure and function. She also directs the University of Minnesota site for the GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study) Trials, and has an active clinical practice.

Dr. Seaquist holds a bachelor's degree from Vassar College, Poughkeepsie, N.Y., and a medical degree from the University of Minnesota in Minneapolis.

As of January 2017, Dr. Seaquist reported the following external relationships:

Funding for clinical trial expenses, staff and salary support paid to the University of Minnesota, from the following companies:

  • Eli Lilly and Company, to assess the cardiovascular safety of dulaglutide.
  • Eli Lilly and Company, for an investigator-initiated trial to examine pharmacokinetics of U-500 insulin.
  • Eli Lilly and Company, for reviewing intra nasal glucagon, dulaglutide, receiving reimbursement for travel expenses and honoraria.

Dr. Seaquist serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Diabetes Association, Mentor Advisory Group, Research Policy Committee, receiving reimbursement for travel expenses.
  • International Hypoglycemia Study Group, receiving reimbursement for travel expenses and honoraria.

Grant support with funding for project expenses, staff, and salary support, paid to the University of Minnesota:

  • George Washington University, for a contract to perform GRADE trial funded by the National Institutes of Health.
  • Juvenile Diabetes Research Foundation, for a trial to determine if N-acetyl cysteine (NAC) is an effective and safe therapy for hypoglycemia unawareness in diabetes.

Deborah Wexler, MD, MSc

Dr. Wexler, who is board certified in Endocrinology, Diabetes, and Metabolism, is Associate Professor of Medicine at Harvard Medical School, the Associate Clinical Chief of the Massachusetts General Hospital (MGH) Diabetes Unit, and co-Clinical Director of the MGH Diabetes Center. She cares for patients with diabetes and general endocrine disorders.

Her research focuses on clinical effectiveness in type 2 diabetes. She is the MGH site Principal Investigator and is on the Executive Committee of the GRADE Study, a NIH-funded multicenter trial to determine which second hypoglycemic drug, added to metformin, is most effective for patients with type 2 diabetes. She is also multiple-Principal Investigator of the REAL HEALTH-Diabetes trial, which will translate the Look AHEAD lifestyle intervention for type 2 diabetes into usual care at community health centers.

Dr. Wexler is a member of the American Board of Internal Medicine Endocrinology, Diabetes and Metabolism Board Exam Committee. She served on the American Diabetes Association’s Professional Practice Committee (2014-2016). Dr Wexler is on the Editorial Board of Diabetes Care and is a reviewer for multiple journals.

She received her medical degree from Yale University School of Medicine, New Haven, Connecticut, and her master of science degree from the University of Oxford as a Marshall Scholar. She completed her internship, residency, and chief residency in internal medicine and fellowship in endocrinology at Massachusetts General Hospital.

As of July 2017, Dr. Wexler reported the following external relationships:

Work as an author or editor for following company, with compensation as listed:

  • Elsevier, receiving compensation as an editor for PracticeUpdate: Diabetes.

Dr. Wexler also reported teaching at Harvard Medical School’s Clinical Endocrinology Continuing Medical Education course.

William F. Young Jr., MD

Dr. Young, a board certified internist and endocrinologist, is the Tyson Family Endocrinology Clinical Professor, and Chair of the Division of Endocrinology, Diabetes, Metabolism, and Nutrition at the Mayo Clinic in Rochester, MN. He is a practicing endocrinologist with an active clinical practice and a dedicated teacher and mentor to residents and endocrinology fellows.

Currently, Dr. Young serves as a member of the American Board of Internal Medicine (ABIM) Council and the ABIM Endocrinology Board Exam Committee, and he serves as Chair of the ABIM Endocrinology, Diabetes, and Metabolism Board. Dr. Young is an internationally recognized endocrinologist who has served as past President of the Endocrine Society, past Chair of the Endocrine Society Self-Assessment Committee, an Associate Editor for the Journal of Clinical Endocrinology and Metabolism, and as a Senior Editor for Clinical Endocrinology. He is past Chair of the Endocrine Society's Annual Meeting Steering Committee and Nominating Committee. Dr. Young has published more than 240 articles on endocrine hypertension and adrenal and pituitary disorders. He has been the recipient of multiple education awards and has presented at over 300 national and international meetings and he has been an invited visiting professor for more than 100 medical institutions.

Dr. Young earned his medical degree at the Michigan State University. He completed his internal medicine residency at William Beaumont Hospital and later completed fellowship training in endocrinology at Mayo Clinic.

As of May 2017, Dr. Young reported the following external relationships:

Funding for preclinical trial expenses and staff from the following company:

  • Nihon-Medi Physics, for animal studies to determine new approach to imaging the adrenal glands with PET-based technologies, receiving consulting fees.

Work as an author or editor for following companies, with compensation as listed:

  • UpToDate, receiving compensation for authorship.
  • Elsevier, receiving compensation for authorship for the book, The Netter Collection of Medical Illustrations: Endocrine System.
  • Wiley-Blackwell, receiving compensation for authorship.

Dr. Young serves in a significant role with the following organizations, receiving reimbursement or compensation as listed:

  • International Society of Endocrinology, serving as an Executive Board Member, without compensation.